Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Theratyping in cystic fibrosis.

Current opinion in pulmonary medicine - 1 Nov 2018

Crawford Kathryn J, Downey Damian G

Abstract excerpt

PURPOSE OF REVIEW: The treatment of cystic fibrosis (CF) with CF transmembrane conductance regulator (CFTR) modulators continues to develop at a fast pace. These compounds are potentially disease modifying but are only available to certain patient subsets based on genotype. This review discusses the role of theratyping in CF and the potential to assess all patients' response to current and emerging therapies....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Aminopyridines
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chloride Channel Agonists

Share to Drug Combinations

Share to Organoids

Share to Oxadiazoles

Share to Quinolones

Source

Identifiers

PMID: 30124524
DOI: 10.1097/MCP.0000000000000521

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Theratyping in cystic fibrosis.PMID 30124524Read ↗

CFTR modulator theratyping: Current status, gaps and future directions.Semantic proximity Read ↗

Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration.Semantic proximity Read ↗

Patient-derived cell models for personalized medicine approaches in cystic fibrosis.Semantic proximity Read ↗

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.Semantic proximity Read ↗

Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells.Semantic proximity Read ↗

Personalized medicine for cystic fibrosis: establishing human model systems.Semantic proximity Read ↗

CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis.Semantic proximity Read ↗

Benchmarking organ-specific responses to therapies in tissues differentiated from Cystic Fibrosis patient derived iPSCsSemantic proximity Read ↗

Targeted Therapy for Restoring CFTR Activity: From Experimental to Clinical Features.Semantic proximity Read ↗

Established and novel human translational models to advance cystic fibrosis research, drug discovery, and optimize CFTR-targeting therapeutics.Semantic proximity Read ↗

Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic FibrosisSemantic proximity Read ↗

Organoid Guided N-of-1 (ORIGIN-1) Clinical Trial: A phase 4 study to investigate if people with cystic fibrosis with rare non-F508del CFTR mutations with an in-vitro response to Elexacaftor/ Tezacaftor/ Ivacaftor have a clinically meaningful response to Elexacaftor/ Tezacaftor/ Ivacaftor versus placebo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.